// App-Quantinova.ai

DDDR-01 : AZD9574 IS A NOVEL, BRAIN PENETRANT PARP-1 SELECTIVE INHIBITOR WITH ACTIVITY IN AN INTRACRANIAL XENOGRAFT MODEL OF TRIPLE NEGATIVE BREAST CARCINOMA WITH HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY

Researchers

Presenter

  • Kunzah Jamal

Principal Investigators

  • Jacob Gordon

  • Domenic Pilger

  • Giuditta Illuzzi

  • Joanne Wilson

  • Aaron Smith

  • Eric Gosselin

  • Lisa McWilliams

  • Shenghua Wen

  • Frank McGrath

  • Gregory Dowdell

  • Dominic Kabbabe

  • Matthew Griffin

  • Barry Davies

  • Petra Hamerlik

  • Magnus Schou

  • Andy Pike

  • Jeffrey Johannes

Medical Centers

  • AstraZeneca, Saffron Walden, United Kingdom

  • AstraZeneca, Stockholm, Sweden

  • AstraZeneca, Waltham, USA

Locations

  • United Kingdom

  • United States

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Poly(ADP-Ribose) Polymerase 1

Drug/Treatment

  • ribose

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved